Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) was the target of a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 1,212,606 shares, a growth of 70.6% from the October 13th total of 710,794 shares. Based on an average daily trading volume, of 2,204,410 shares, the days-to-cover ratio is presently 0.6 days. Approximately 6.7% of the shares of the company are sold short.
Imprimis Pharmaceuticals (IMMY) opened at $1.66 on Thursday. Imprimis Pharmaceuticals has a 12 month low of $1.35 and a 12 month high of $4.69. The company has a quick ratio of 1.55, a current ratio of 1.88 and a debt-to-equity ratio of 1.68.
A number of hedge funds and other institutional investors have recently bought and sold shares of IMMY. KCG Holdings Inc. acquired a new stake in Imprimis Pharmaceuticals in the 1st quarter worth $130,000. Bank of New York Mellon Corp grew its position in Imprimis Pharmaceuticals by 60.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 35,606 shares of the specialty pharmaceutical company’s stock worth $114,000 after purchasing an additional 13,455 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in Imprimis Pharmaceuticals by 78.2% in the 2nd quarter. Vanguard Group Inc. now owns 451,226 shares of the specialty pharmaceutical company’s stock worth $1,444,000 after purchasing an additional 198,068 shares during the last quarter. Institutional investors own 17.88% of the company’s stock.
Imprimis Pharmaceuticals, Inc (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment.
Receive News & Ratings for Imprimis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.